Literature DB >> 1467515

Granulocyte-macrophage colony-stimulating factor and erythropoietin act competitively to induce two different programs of differentiation in the human pluripotent cell line UT-7.

O Hermine1, P Mayeux, M Titeux, M T Mitjavila, N Casadevall, J Guichard, N Komatsu, T Suda, Y Miura, W Vainchenker.   

Abstract

The UT-7 cell line was established from a patient with a megakaryoblastic leukemia (Komatsu et al, Cancer Res 51: 341, 1991). Its proliferation is strictly dependent on the presence of hematopoietic growth factors including erythropoietin (Epo), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-3 (IL-3). We investigated the differentiation capacities of this cell line under the action of several growth factors, using immunomarkers, flow cytometry, and ultrastructural techniques. In the presence of GM-CSF and IL-3, eosinophil and basophil promyelocytes were detected, as well as a few cells with erythroid and megakaryocytic (MK) differentiation features. In contrast, Epo induced a marked erythroid differentiation with an increase of glycophorin A expression, accompanied by a few hemoglobinized cells. Differentiation induced by the growth factors took 24 to 48 hours to begin, and increased with cell passages to a plateau at 2 weeks of culture. However, this was not only due to a cell selection because the differential effects of Epo and GM-CSF were observed from a single cell clone and the phenotype could be reversed by opposite growth factors, even after a long period of culture. We subsequently investigated the phenotype of UT-7 in the presence of combinations of Epo, IL-3, and GM-CSF, and showed that GM-CSF and IL-3 act predominantly over Epo. This effect was mediated by a rapid downmodulation of Epo receptors by GM-CSF at messenger RNA and binding sites levels, without a change in receptor affinities. On the other hand, Epo had no effect on number and affinity of GM-CSF receptors. This study shows that UT-7 is a growth factor-dependent pluripotent cell line in which commitment may be directed by a hierarchical action of growth factors through an early and rapid transmodulation of growth factor receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467515

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Human B19 erythrovirus in vitro replication: what's new?

Authors:  Sylvie Pillet; Serge Fichelson; Frédéric Morinet; Neal S Young; Ning Zhi; Susan Wong
Journal:  J Virol       Date:  2008-09       Impact factor: 5.103

2.  Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin.

Authors:  F Porteu; M C Rouyez; L Cocault; L Bénit; M Charon; F Picard; S Gisselbrecht; M Souyri; I Dusanter-Fourt
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.

Authors:  S Chrétien; P Varlet; F Verdier; S Gobert; J P Cartron; S Gisselbrecht; P Mayeux; C Lacombe
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

4.  Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity.

Authors:  F Gouilleux; C Pallard; I Dusanter-Fourt; H Wakao; L A Haldosen; G Norstedt; D Levy; B Groner
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

5.  Immortalization of multipotent growth-factor dependent hemopoietic progenitors from mice transgenic for GATA-1 driven SV40 tsA58 gene.

Authors:  L A Cairns; S Crotta; M Minuzzo; E Moroni; F Granucci; S Nicolis; R Schiró; L Pozzi; B Giglioni; P Ricciardi-Castagnoli
Journal:  EMBO J       Date:  1994-10-03       Impact factor: 11.598

6.  Thrombopoietin activates a STAT5-like factor in hematopoietic cells.

Authors:  C Pallard; F Gouilleux; L Bénit; L Cocault; M Souyri; D Levy; B Groner; S Gisselbrecht; I Dusanter-Fourt
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.